Abstract
INTRODUCTION
Calcineurin inhibitors (CNIs) are the main immuno suppressive agents utilized in kidney transplantation [1] . Cyclosporine (CYA) and tacrolimus (FK) are currently the most widely used maintenance immunosuppressants for prevention of acute rejection in kidney transplant recipients. CYAbased regimen was more common in the era of 1990 until 2002, after which FKbased regimen became more commonly used in most transplant pro grams. In our transplant center, FK became the primary CNI of choice in 2005. FK and CYA show variable side effect profiles. Hypertension, hyperlipidemia, gum hypertrophy, and hirsutism occur more frequently with CYA use. On the other hand, a higher incidence of post transplant diabetes mellitus is observed with FK therapy. Prolonged use of CNI may result in nephrotoxicity.
FK use is associated with less acute rejection compared to CYA, as documented in different studies [2, 3] . Mayer et al [2] found that among 448 renal transplant recipients who were on triple therapy (FK or CYA + Azathioprine + Prednisone), patients who were in the FK group had a significant reduction in the frequency of acute rejection at 12 mo (FK 25.9% vs CYA 45.7%; P < 0.001). Ekberg et al [3] also found that at 12 mo post transplant, the use of FKbased regimen is associated with less biopsyproven acute rejection compared to CYA use (12.3% vs 25.8%, P < 0.01). FK is frequently preferred in patients with high immunologic risk (highly sensitized, ABOincompatible organ recipients), delayed graft function, and African American race. Data regarding graft survival based on the use of FK vs CYA is controversial with most studies showing similar graft survival rates with the use of either agent [4] . Vincenti et al [5] showed comparable patient (79.1% vs 81.4%; P = 0.472) and graft (64.3% vs 61.6%; P = 0.558) survival between treatment arms at 5 years of followup among FK and CYAtreated patients. However, after accounting for patients initially on CYA who crossed over to FK, the authors found significantly reduced graft failure in the FK group [5] . Gonwa et al [6] showed that among 223 kidney transplant recipients who experienced delayed graft function, patients who used FKbased therapy had a better 3year graft survival compared to CYA use (84.1% vs 49.9%, P = 0.02). Given these conflicting findings, this study aims to compare rates of acute rejection and graft loss among patients who receive FK and CYA.
MATERIALS AND METHODS

Patients
This was a retrospective cohort study of 1835 patients who received a KTX between 19992012 at a single center. Patients were grouped based on the type of CNI they were prescribed: 1195 patients utilized FKbased immunosuppression whereas 640 patients were on a CYA based regimen. All patients received an antimetabolite and prednisone in combination with CNI. The initial CYA dose was 45 mg/kg PO BID. Target CYA levels were 350400 ng/mL for weeks 14, 250350 ng/mL for weeks 512, 200-300 ng/mL within the first year post-transplant, and 100200 ng/mL thereafter. Initial FK doses were given at 0.0250.05 mg/kg PO BID. Target FK levels were kept between 812 ng/mL within the first four weeks post transplant, then 6-10 ng/mL within the first year posttransplant, and 46 ng/mL subsequently. 
Statistical analysis
The statistical review was performed by a clinician with advanced biostatistical training and experience. Twosided independent student's ttest was used to compare continuous data while the χ 2 test was used to compare categorical data. A twosided Pvalue of less than 0.05 was considered statistically significant. Multivariate survival analysis, using both logistic and Cox regression, was used to assess the association between CNI choice and acute rejection (logistic), graft survival (Cox), and patient mortality (Cox), while controlling for additional transplant variables known to influence outcomes or those that differed across CNI choice. In a subset analysis of patients who had graft loss, causes of graft loss, and causes of death were compared between the two groups using standard univariate comparative statistics. All analyses were conducted using SPSS version 21.0 (IBM Corp, Armonk, NY). Table 1 displays demographic characteristics of the two groups. Mean recipient age, race, BMI, etiology of kidney disease, comorbidities, and dialysis vintage, were similar between the two groups. Patients on FK had higher PRA compared to patients on CYA group (17% vs 5%, P < 0.01). Rates of living donor transplants were similar between the two groups. Among patients who received a deceased donor transplant, KDRI was higher in those who received FK. More patients in the FK group received induction agent with depleting antibodies (46% vs 11%, P < 0.01).
RESULTS
Patient characteristics
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December 24, 2016|Volume 6|Issue 4| WJT|www.wjgnet.com in the majority of these patients. The leading causes of death among the patients include cardiovascular disease, infections, and malignancies (Table 5 ). The contribution of nonadherence and underimmunosuppression in pa tients who had graft loss was not significantly different between the FK and CYA groups.
DISCUSSION
The utilization of potent immunosuppressive medications such as CYA and FK has led to progressive improvement in renal allograft survival. Two large studies on kidney transplant recipients showed that the incidence of acute rejection is much lower with FKbased immunosuppression compared to CYAbased regimen [2, 3] . Our study demon strated similar findings of lower acute rejection rates in patients using FK compared to those on CYA. Acute rejection rate was significantly lower in the FK group despite the relatively higher degree of sensitization, as evidenced by higher PRA, in this group. Multivariate analysis showed that FK was a strong predictor for lower acute rejection rates while controlling for recipient, donor, and transplant characteristics.
The shortage of deceased donor kidneys and the growing number of patients on the waiting list has driven the increased utilization of organs with relatively marginal donor characteristics. Donor factors affect initial graft function and survival [7] . Donor factors that may influence graft survival include age, gender, hypertension, and cardiovascular disease [8] . The KDRI is a comprehensive metric that was recently developed to assess the relative risk of graft failure associated with various combinations of donor characteristics. Kidneys with the highest KDRI quintile are associated with lower graft survival [9] . Although many trials have shown similar graft survival outcomes with FK when compared with CYAbased regimen [4] , some studies showed better survival and outcomes with FKbased immunosuppression [6] . Our
Clinical outcomes
Patients in the FK group had better clinical outcomes in terms of delayed graft function (DGF) rate (15% vs 18%, P = 0.049), cumulative biopsy proven acute rejection rates for Banff 1A and higher, as well as antibodymediated rejection (14% vs 24%, P < 0.01), three year graft survival (88% vs 79%, P < 0.010), and five year graft survival (84% vs 70%, P < 0.01) ( Table  2) . FK was a strong predictor of lower acute rejection rates. After multivariate analysis, which accounted for recipient immunologic risks (age, gender, retransplant, PRA, HLA mismatches, cold ischemic time, induction), donor characteristics (deceased status, ECD, age, race) and delayed graft function, FK continued to be strongly associated with lower acute rejection rates, as compared to CYA (OR = 0.60, 95%CI: 0.450.79; P < 0.001) ( Table 3 ). Further analysis showed that even after controlling for all other variables, including delayed graft function and acute rejection, FK remained a strong and statistically significant predictor of graft survival (OR = 0.740, 95%CI: 0.580.94; P = 0.012) (Table 4) (Figure 1 ).
Graft loss
During the study period, there were 106 patients in the FK group and 123 in the CYA group who had graft loss. Death with a functioning graft was the cause of graft loss Kamel M et al . Renal allograft survival with tacrolimus study showed that although patients in the FK group received kidneys from more marginal donors (higher KDRI), the three year and five year graft survival was still more superior in this group compared to the CYA group (Figure 1 ). The risk of infections after kidney transplant de pends on the net state of immunosuppression. As FK was shown to be associated with less acute rejection compared to CYA [10] , it may concurrently cause more intense immunosuppressive effects compared to CYA. Thus, risk of infections after kidney transplant may be higher with FK compared to CYA. This may be exemplified by the higher incidence of polyomavirus (BK) viremia in patients on FKbased regimen compared to CYA [11] . Progression of BK viremia may lead to BK nephropathy, which can then eventually cause premature renal allograft failure [11] . However, in our subjects who had graft loss, we did not observe a significant difference in the prevalence of infections (including BK) in the FK and CYA groups.
The use of maintenance immunosuppressive medi cations among transplant recipients increases the long term risk of malignancy, compared with that of the general population. The overall level of immunosuppression appears to be the principal factor that increases the risk of post transplant malignancy. Both FK and CYA are associated with an increased risk of malignancy following kidney transplant [12, 13] . No direct comparison between these two agents has been reported regarding the incidence of malignancy following kidney transplant. However, FK was found to have higher incidence of de novo malignancy after liver transplant compared to CYA [14] . In our study, we did not find a significant difference in the prevalence of malignancies between the two groups.
Cardiovascular disease is a leading cause of mortality among kidney transplant recipients. Death from cardio vascular disease is the most common cause of renal allograft loss [15] . CNIs potentially contribute to increased risk of cardiovascular events indirectly by the development of newonset diabetes mellitus, hypertension, and hyperlipidemia. Clinical trials have shown a higher inci dence of posttransplant diabetes mellitus with FK. However, the risk of hypertension and hyperlipidemia is slightly higher with CYA than FK. No direct comparison has been done between FK and CYA regarding the incidence of cardiovascular disease. In our study, we found that FK was associated with a slightly higher prevalence of cardiovascular disease compared to CYA, although the difference was not statistically significant.
In conclusion, FK is associated with lower prevalence of acute rejection compared to CYA. It confers better three and five year graft survival even with the use of 
COMMENTS
Background
Calcineurin inhibitors (CNIs) [cyclosporine (CYA) and tacrolimus (FK)] are currently the most widely used maintenance immunosuppressants for prevention of acute rejection following kidney transplantation. However, data on the impact of these CNIs on acute rejection rate and graft survival have remained equivocal.
Research frontiers
The choice of immunosuppressive regimen that will achieve the best renal allograft outcomes remains an important focus in the care of kidney transplant recipients.
Innovations and breakthroughs
The data showed lower acute rejection rates and better graft survival in patients on FK compared to those on CYA.
Applications
The use of either FK or CYA should be individualized based on patient's comorbidities and immunological risk. 
